GRAIL, Inc. (GRAL) は上場企業です ヘルスケア セクターの Medical - Diagnostics & Research 業界で事業展開. 本社所在地は Menlo Park, CA, アメリカ. 現CEOは Robert Ragusa.
GRAL を有する IPO日 2024-06-12, 1,000 名の正社員, に上場 NASDAQ Global Market, 時価総額 $2.07B.
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
